Prescient shareholder webinar

Phase 2a PTX-100 CTCL study Dose optimisation review outcome

MELBOURNE Australia, 27 November 2026 – Prescient Therapeutics (ASX: PTX), a clinical-stage oncology company developing targeted cancer therapies, invites shareholders and investors to an investor webinar on Tuesday 8 December 2026 at 11am AEDT.

CEO James McDonnell will present:

- A review of the outcome of the first Dose Optimisation Committee (DOC) review of the Phase 2a study of PTX-100 in relapsed or refractory cutaneous T-cell lymphoma (CTCL), announced on 25 November 2026
- A summary of the Board's initial review of the PTX-100 program subsequent to the DOC meeting
- Current considerations for rebuilding shareholder value

On 25 November 2026, Prescient announced that the DOC had completed its first review of data from the ongoing Phase 2a study. PTX-100 was well tolerated, with no serious adverse events related to PTX-100. Of the 20 participants evaluable for efficacy, 2 achieved a complete response, 12 had stable disease and 6 had disease progression.

The DOC considered the available data insufficient to select a dose and recommended that enrolment continue. The Company advised it would undertake a review of the PTX-100 program in light of the clinical data and the DOC's recommendation, with enrolment continuing while the review is undertaken.

Webinar details – register now

- Date: Tuesday 8 December 2026
- Time: 11am AEDT
- Registration: https://prescienttherapeutics.investorportal.com.au/investor-briefing/

Once registered, participants will receive a confirmation email with instructions for joining. A recording will be available on the Company's website after the event.

To stay updated with the latest company news and announcements, please update your details in our investor centre.

The disclosure committee of Prescient Therapeutics Limited has approved the release of this announcement.

For more information please contact:

Company enquiries

James McDonnell
CEO
Prescient Therapeutics
james.mcdonnell@ptxtherapeutics.com

Investor and media enquiries

Patrick Nelson
Reach Markets
1300 805 795
ir@reachmarkets.com.au

About Prescient Therapeutics Limited (Prescient)

Prescient Therapeutics is a clinical-stage oncology company developing personalised cancer treatments through targeted therapies and advanced cell therapy enhancement platforms.

Targeted Therapy

PTX-100 is a first-in-class compound with the ability to block an enzyme that can contribute to cancer growth known as geranylgeranyl transferase-1 (GGTase-1). Blocking this target disrupts oncogenic Ras pathways by inhibiting the activation of Rho, Rac and Ral signaling circuits in cancer cells, leading to their apoptosis (death). Mutations in Ras pathways are believed to be involved in up to 22% of all cancers.

PTX-100 demonstrated safety and early clinical activity in a previous Phase 1 study and in a recent PK/PD basket study of hematological and solid malignancies. PTX-100 has recently completed a Phase 1b expansion cohort study in T-cell lymphomas, where it showed encouraging efficacy and safety. The US FDA has granted PTX-100 Orphan Drug Designation for all T-Cell Lymphomas and Fast Track Designation for the treatment of adults with relapsed or refractory (r/r) mycosis fungoides, the most common subtype of CTCL. The Phase 2 study in r/r Cutaneous T-cell lymphoma (CTCL) completed its first Dose Optimisation Committee review of 20 evaluable patients (10 in each dosing arm). The Board is reviewing next steps for the program.

Cell Therapy Platforms

OmniCAR: is a universal immune receptor platform enabling controllable T-cell activity and multi-antigen targeting with a single cell product. OmniCAR's modular CAR system decouples antigen recognition from the T-cell signalling domain. It is the first universal immune receptor allowing post-translational covalent loading of binders to T-cells. OmniCAR is based on technology licensed from Penn; the

SpyTag/SpyCatcher binding system licensed from Oxford University; and other assets. OmniCAR is in preclinical development.

The targeting ligand can be administered separately to CAR-T cells, creating on-demand T-cell activity post infusion and enables the CAR-T to be directed to an array of different tumour antigens. OmniCAR provides a method for single-vector, single cell product targeting of multiple antigens simultaneous or sequentially, whilst allowing continual re-arming to generate, regulate and diversify a sustained T-cell response over time.

CellPryme-A: CellPryme-A is an adjuvant therapy designed to be administered to patients alongside cellular immunotherapy to help them overcome a suppressive tumour microenvironment. CellPryme-A significantly decreases suppressive regulatory T cells; increases expansion of CAR-T cells in vivo; increases tumour penetration of CAR-T cells. CellPryme-A improves tumour killing and host survival of CAR-T cell therapies, and these benefits are even greater when used in conjunction with CellPryme-M pretreated CAR-T cells.

CellPryme-M: Prescient's novel, ready-for-the-clinic, CellPryme-M technology enhances adoptive cell therapy performance by shifting T cells towards a central memory phenotype, improving persistence, and increasing the ability to find and penetrate tumours. CellPryme-M is a 24-hour, non-disruptive process during cell manufacturing. Cell therapies that could benefit from additional productivity in manufacturing or increased potency and durability in-vivo, would be good candidates for CellPryme-M.

Find out more at www.ptxtherapeutics.com or connect with us via LinkedIn.

Forward Looking Statements

This announcement contains forward-looking statements based on current expectations, estimates, and assumptions. These statements are subject to risks and uncertainties that may cause actual results to differ materially. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this announcement. Prescient undertakes no obligation to revise forward-looking statements except as required by law.